Related and unrelated cord blood donors for SCD
| Reference . | Transplant regimen . | Median TNC dose, × 107/kg (range) . | HLA match . | Number of patients (age range) . | Alive without SCD . | Acute GVHD . | Chronic GVHD . | Death (cause) . |
|---|---|---|---|---|---|---|---|---|
| Related cord blood donors | ||||||||
| Brichard et al, 199664 | Bu 16 mg/kg, Cy 200 mg/kg, ATG, CSA | 4.6 | 6/6 | 1 (5) | 1 | 0 | 0 | N/A |
| Miniero et al, 199865 | Bu 16 mg/kg, Cy 200 mg/kg, CSA ± MTX | (3.5-6.0) | 6/6 | 3 (3-11) | 2 | 2 (Gr 1) | 0 | N/A |
| Gore et al, 200066 | Bu 726 mg/m2, Cy 200 mg/kg, ATG, CSA | 2.3 | 6/6 | 1 (9) | 1 | 0 | 0 | N/A |
| Locatelli et al, 200367 | Mostly Bu, Cy, ATG/ALG, CSA ± MTX | 4.0 (1.2-10)* | 6/6 41 pts, 5/6 3 pts* | 11 (1-20)* | 10 | 11% (Gr 2)* | 6% (limited)* | N/A |
| Walters et al, 200568 | NR | NR | 6/6 42 pts, 4/6 4 pts† | 8 (NR) | 6 | NR | NR | 1 (intractable seizures) |
| Unrelated cord blood donors | ||||||||
| Adamkiewicz et al, 200769 | Mixed, 4 pts myeloablative, 3 pts reduced intensity | (1.5-9.3) | 5/6 2 pts, 4/6 5 pts | 7 (3.4-16.8) | 3 | 1 (Gr 1); 2 (Gr 2); 1 (Gr 3); 1 (Gr 4) | 1 (extensive) | 1 (multiorgan failure) |
| Mazur et al, 200670 | Rituximab, alemtuzumab, thiotepa (600 mg/m2), 600 cGy TBI, tac + MMF‡ | 4.2 | 4/6 | 1 (9) | 1 | Gr 1 | 0 | N/A |
| Sauter et al, 201071 | Reduced intensity | 3.8 and 2.0§ | 5/6 | 1 (22) | 1 | 0 | 0 | N/A |
| Reference . | Transplant regimen . | Median TNC dose, × 107/kg (range) . | HLA match . | Number of patients (age range) . | Alive without SCD . | Acute GVHD . | Chronic GVHD . | Death (cause) . |
|---|---|---|---|---|---|---|---|---|
| Related cord blood donors | ||||||||
| Brichard et al, 199664 | Bu 16 mg/kg, Cy 200 mg/kg, ATG, CSA | 4.6 | 6/6 | 1 (5) | 1 | 0 | 0 | N/A |
| Miniero et al, 199865 | Bu 16 mg/kg, Cy 200 mg/kg, CSA ± MTX | (3.5-6.0) | 6/6 | 3 (3-11) | 2 | 2 (Gr 1) | 0 | N/A |
| Gore et al, 200066 | Bu 726 mg/m2, Cy 200 mg/kg, ATG, CSA | 2.3 | 6/6 | 1 (9) | 1 | 0 | 0 | N/A |
| Locatelli et al, 200367 | Mostly Bu, Cy, ATG/ALG, CSA ± MTX | 4.0 (1.2-10)* | 6/6 41 pts, 5/6 3 pts* | 11 (1-20)* | 10 | 11% (Gr 2)* | 6% (limited)* | N/A |
| Walters et al, 200568 | NR | NR | 6/6 42 pts, 4/6 4 pts† | 8 (NR) | 6 | NR | NR | 1 (intractable seizures) |
| Unrelated cord blood donors | ||||||||
| Adamkiewicz et al, 200769 | Mixed, 4 pts myeloablative, 3 pts reduced intensity | (1.5-9.3) | 5/6 2 pts, 4/6 5 pts | 7 (3.4-16.8) | 3 | 1 (Gr 1); 2 (Gr 2); 1 (Gr 3); 1 (Gr 4) | 1 (extensive) | 1 (multiorgan failure) |
| Mazur et al, 200670 | Rituximab, alemtuzumab, thiotepa (600 mg/m2), 600 cGy TBI, tac + MMF‡ | 4.2 | 4/6 | 1 (9) | 1 | Gr 1 | 0 | N/A |
| Sauter et al, 201071 | Reduced intensity | 3.8 and 2.0§ | 5/6 | 1 (22) | 1 | 0 | 0 | N/A |
ALG indicates antilymphocyte globulin; ATG, antithymocyte globulin; Bu, busulfan; cGy, centi-Gray; CSA, cyclosporine A; Cy, cyclophosphamide; Gr, grade; MMF, mycophenolate mofetil; MTX, methotrexate; N/A, not applicable; pts, patients; NR, not reported; SCD, sickle cell disease; tac, tacrolimus; TBI, total body irradiation; and TNC, total nucleated cell.
Includes 44 patients in the entire cohort: 33 patients with thalassemia and 11 patients with SCD.
Includes 47 patients in the entire cohort: 14 patients with thalassemia, 8 patients with SCD, and 25 other.
This represents a second unrelated umbilical cord blood transplantation.
Patient received a double umbilical cord unit transplantation.